Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2025-08-27 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
董事会秘书工作细则
Governance Information Classification · 95% confidence The document is titled '董事会秘书工作细则' which translates to 'Board Secretary Work Rules' or 'Board Secretary Operational Guidelines'. It details the duties, qualifications, appointment, and legal responsibilities of the company's board secretary. It references relevant laws and regulations governing board secretary roles and company governance. There is no financial data, no report of financial results, no announcement of voting results, no audit information, no earnings data, no capital or financing update, no merger or acquisition information, and no legal proceeding updates. The document is a governance-related internal rules document about the board secretary's role and responsibilities. Therefore, it fits best under the category 'Governance Information (CGR)'. The document length is 3202 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Hence, the classification is CGR with high confidence.
2025-08-27 Chinese
总经理工作细则
Governance Information Classification · 95% confidence The document is a detailed internal work procedure for the General Manager of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It outlines the roles, responsibilities, appointment conditions, and operational rules for the General Manager and other senior management positions. There is no financial data, no mention of financial results, no shareholder voting information, no legal proceedings, no capital changes, no earnings announcements, and no regulatory filings. The document is a governance-related internal policy document describing management roles and corporate governance practices. Therefore, it fits best under Governance Information (CGR). The document length is sufficient and it is not a brief announcement or certification, so it is not RPA or RNS.
2025-08-27 Chinese
上海泓博智源医药股份有限公司章程修订对照表
Governance Information Classification · 95% confidence The document is a detailed comparison table of amendments to the Articles of Association (章程修订对照表) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It contains extensive legal and governance language about company structure, shareholder rights, board responsibilities, capital, and other corporate governance matters. There is no indication of financial statements, audit opinions, earnings data, or other financial performance information. The content focuses on governance rules, board and shareholder meeting powers, and company bylaws. This aligns with the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is lengthy and substantive, not a mere announcement or notice, so it is not an RPA or RNS. Therefore, the appropriate classification is CGR with high confidence.
2025-08-27 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 年半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, total assets, and shareholder information for the half-year period. The document is about 3,255 characters long, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. It is clearly a financial report for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. There is no indication that this is merely an announcement or a certification, and it includes actual financial figures and business information. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2025
2025-08-27 Chinese
对外担保管理制度
Governance Information Classification · 95% confidence The document is titled '对外担保管理制度' which translates to 'External Guarantee Management System' and is issued by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the company's internal policies and procedures regarding external guarantees, including principles, approval management, contract signing, risk management, and responsibility accountability. The document references relevant laws and regulations but does not contain financial statements, earnings data, or regulatory filings. It is a governance-related internal policy document rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-27 Chinese
内部审计制度
Governance Information Classification · 95% confidence The document is titled '内部审计制度' which translates to 'Internal Audit System' or 'Internal Audit Policy' of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the internal audit framework, responsibilities, procedures, and governance within the company. It includes descriptions of the audit committee, internal audit functions, audit scope, reporting, and disciplinary measures. There is no indication that this is a standalone audit report, an annual report, or any financial statement. It is a governance and procedural document related to internal audit policies and internal control systems. It does not contain financial data or results but rather outlines the internal audit system and governance structure. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.